The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Synopsis
Parkinson’s disease (PD) is a chronic and progressive disease, considered an idiopathic form, and accounts for roughly 80% of the cases of Parkinsonism—neurological disorders that lead to movement problems. While the exact cause of Parkinson’s disease is unknown, it may include a number of factors such as aging, environmental factors/exposures, and genetic predispositions.
The global Parkinson’s Disease Treatment market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Parkinson’s Disease Treatment is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Parkinson’s Disease Treatment is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Parkinson’s Disease Treatment in Hospital Pharmacy is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Parkinson’s Disease Treatment include Teva, Roche, Prothena, Acorda Therapeutics, Voyager Therapeutics, Impax Pharmaceuticals, UCB, AbbVie and MSD, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Parkinson’s Disease Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Parkinson’s Disease Treatment.
Report Scope
The Parkinson’s Disease Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Parkinson’s Disease Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Parkinson’s Disease Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company (Partial List)
- Teva
- Roche
- Prothena
- Acorda Therapeutics
- Voyager Therapeutics
- Impax Pharmaceuticals
- UCB
- AbbVie
- MSD
- Orion Pharmaceuticals
- Intec Pharma
- NeuroDerm
- Adamas Therapeutics
- Acadia
- Sunovion
- GSK
Segment by Type
- Oral
- Transdermal
- Subcutaneous
- Intestinal Infusion
Segment by Application
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Consumption by Region
- North America (United States, Canada)
- Europe (Germany, France, U.K., Italy, Netherlands)
- Asia-Pacific (China, Japan, South Korea, China Taiwan, Southeast Asia, India)
- Latin America, Middle East & Africa (Latin America, Mexico, Brazil, Turkey)
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Parkinson’s Disease Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Parkinson’s Disease Treatment Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Oral
1.2.3 Transdermal
1.2.4 Subcutaneous
1.2.5 Intestinal Infusion
1.3 Market by Application
1.3.1 Global Parkinson’s Disease Treatment Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.3.4 Online Pharmacy
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Parkinson’s Disease Treatment Market Perspective (2019-2030)
2.2 Parkinson’s Disease Treatment Growth Trends by Region
2.2.1 Global Parkinson’s Disease Treatment Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Parkinson’s Disease Treatment Historic Market Size by Region (2019-2024)
2.2.3 Parkinson’s Disease Treatment Forecasted Market Size by Region (2025-2030)
2.3 Parkinson’s Disease Treatment Market Dynamics
2.3.1 Parkinson’s Disease Treatment Industry Trends
2.3.2 Parkinson’s Disease Treatment Market Drivers
2.3.3 Parkinson’s Disease Treatment Market Challenges
2.3.4 Parkinson’s Disease Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Parkinson’s Disease Treatment Players by Revenue
3.1.1 Global Top Parkinson’s Disease Treatment Players by Revenue (2019-2024)
3.1.2 Global Parkinson’s Disease Treatment Revenue Market Share by Players (2019-2024)
3.2 Global Parkinson’s Disease Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Parkinson’s Disease Treatment Revenue
3.4 Global Parkinson’s Disease Treatment Market Concentration Ratio
3.4.1 Global Parkinson’s Disease Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Parkinson’s Disease Treatment Revenue in 2023
3.5 Parkinson’s Disease Treatment Key Players Head office and Area Served
3.6 Key Players Parkinson’s Disease Treatment Product Solution and Service
3.7 Date of Enter into Parkinson’s Disease Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Parkinson’s Disease Treatment Breakdown Data by Type
4.1 Global Parkinson’s Disease Treatment Historic Market Size by Type (2019-2024)
4.2 Global Parkinson’s Disease Treatment Forecasted Market Size by Type (2025-2030)
5 Parkinson’s Disease Treatment Breakdown Data by Application
5.1 Global Parkinson’s Disease Treatment Historic Market Size by Application (2019-2024)
5.2 Global Parkinson’s Disease Treatment Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Parkinson’s Disease Treatment Market Size (2019-2030)
6.2 North America Parkinson’s Disease Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Parkinson’s Disease Treatment Market Size by Country (2019-2024)
6.4 North America Parkinson’s Disease Treatment Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Parkinson’s Disease Treatment Market Size (2019-2030)
7.2 Europe Parkinson’s Disease Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Parkinson’s Disease Treatment Market Size by Country (2019-2024)
7.4 Europe Parkinson’s Disease Treatment Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Parkinson’s Disease Treatment Market Size (2019-2030)
8.2 Asia-Pacific Parkinson’s Disease Treatment Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Parkinson’s Disease Treatment Market Size by Region (2019-2024)
8.4 Asia-Pacific Parkinson’s Disease Treatment Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Parkinson’s Disease Treatment Market Size (2019-2030)
9.2 Latin America Parkinson’s Disease Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Parkinson’s Disease Treatment Market Size by Country (2019-2024)
9.4 Latin America Parkinson’s Disease Treatment Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Parkinson’s Disease Treatment Market Size (2019-2030)
10.2 Middle East & Africa Parkinson’s Disease Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Parkinson’s Disease Treatment Market Size by Country (2019-2024)
10.4 Middle East & Africa Parkinson’s Disease Treatment Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Teva
11.1.1 Teva Company Detail
11.1.2 Teva Business Overview
11.1.3 Teva Parkinson’s Disease Treatment Introduction
11.1.4 Teva Revenue in Parkinson’s Disease Treatment Business (2019-2024)
11.1.5 Teva Recent Development
11.2 Roche
11.2.1 Roche Company Detail
11.2.2 Roche Business Overview
11.2.3 Roche Parkinson’s Disease Treatment Introduction
11.2.4 Roche Revenue in Parkinson’s Disease Treatment Business (2019-2024)
11.2.5 Roche Recent Development
11.3 Prothena
11.3.1 Prothena Company Detail
11.3.2 Prothena Business Overview
11.3.3 Prothena Parkinson’s Disease Treatment Introduction
11.3.4 Prothena Revenue in Parkinson’s Disease Treatment Business (2019-2024)
11.3.5 Prothena Recent Development
11.4 Acorda Therapeutics
11.4.1 Acorda Therapeutics Company Detail
11.4.2 Acorda Therapeutics Business Overview
11.4.3 Acorda Therapeutics Parkinson’s Disease Treatment Introduction
11.4.4 Acorda Therapeutics Revenue in Parkinson’s Disease Treatment Business (2019-2024)
11.4.5 Acorda Therapeutics Recent Development
11.5 Voyager Therapeutics
11.5.1 Voyager Therapeutics Company Detail
11.5.2 Voyager Therapeutics Business Overview
11.5.3 Voyager Therapeutics Parkinson’s Disease Treatment Introduction
11.5.4 Voyager Therapeutics Revenue in Parkinson’s Disease Treatment Business (2019-2024)
11.5.5 Voyager Therapeutics Recent Development
11.6 Impax Pharmaceuticals
11.6.1 Impax Pharmaceuticals Company Detail
11.6.2 Impax Pharmaceuticals Business Overview
11.6.3 Impax Pharmaceuticals Parkinson’s Disease Treatment Introduction
11.6.4 Impax Pharmaceuticals Revenue in Parkinson’s Disease Treatment Business (2019-2024)
11.6.5 Impax Pharmaceuticals Recent Development
11.7 UCB
11.7.1 UCB Company Detail
11.7.2 UCB Business Overview
11.7.3 UCB Parkinson’s Disease Treatment Introduction
11.7.4 UCB Revenue in Parkinson’s Disease Treatment Business (2019-2024)
11.7.5 UCB Recent Development
11.8 AbbVie
11.8.1 AbbVie Company Detail
11.8.2 AbbVie Business Overview
11.8.3 AbbVie Parkinson’s Disease Treatment Introduction
11.8.4 AbbVie Revenue in Parkinson’s Disease Treatment Business (2019-2024)
11.8.5 AbbVie Recent Development
11.9 MSD
11.9.1 MSD Company Detail
11.9.2 MSD Business Overview
11.9.3 MSD Parkinson’s Disease Treatment Introduction
11.9.4 MSD Revenue in Parkinson’s Disease Treatment Business (2019-2024)
11.9.5 MSD Recent Development
11.10 Orion Pharmaceuticals
11.10.1 Orion Pharmaceuticals Company Detail
11.10.2 Orion Pharmaceuticals Business Overview
11.10.3 Orion Pharmaceuticals Parkinson’s Disease Treatment Introduction
11.10.4 Orion Pharmaceuticals Revenue in Parkinson’s Disease Treatment Business (2019-2024)
11.10.5 Orion Pharmaceuticals Recent Development
11.11 Intec Pharma
11.11.1 Intec Pharma Company Detail
11.11.2 Intec Pharma Business Overview
11.11.3 Intec Pharma Parkinson’s Disease Treatment Introduction
11.11.4 Intec Pharma Revenue in Parkinson’s Disease Treatment Business (2019-2024)
11.11.5 Intec Pharma Recent Development
11.12 NeuroDerm
11.12.1 NeuroDerm Company Detail
11.12.2 NeuroDerm Business Overview
11.12.3 NeuroDerm Parkinson’s Disease Treatment Introduction
11.12.4 NeuroDerm Revenue in Parkinson’s Disease Treatment Business (2019-2024)
11.12.5 NeuroDerm Recent Development
11.13 Adamas Therapeutics
11.13.1 Adamas Therapeutics Company Detail
11.13.2 Adamas Therapeutics Business Overview
11.13.3 Adamas Therapeutics Parkinson’s Disease Treatment Introduction
11.13.4 Adamas Therapeutics Revenue in Parkinson’s Disease Treatment Business (2019-2024)
11.13.5 Adamas Therapeutics Recent Development
11.14 Acadia
11.14.1 Acadia Company Detail
11.14.2 Acadia Business Overview
11.14.3 Acadia Parkinson’s Disease Treatment Introduction
11.14.4 Acadia Revenue in Parkinson’s Disease Treatment Business (2019-2024)
11.14.5 Acadia Recent Development
11.15 Sunovion
11.15.1 Sunovion Company Detail
11.15.2 Sunovion Business Overview
11.15.3 Sunovion Parkinson’s Disease Treatment Introduction
11.15.4 Sunovion Revenue in Parkinson’s Disease Treatment Business (2019-2024)
11.15.5 Sunovion Recent Development
11.16 GSK
11.16.1 GSK Company Detail
11.16.2 GSK Business Overview
11.16.3 GSK Parkinson’s Disease Treatment Introduction
11.16.4 GSK Revenue in Parkinson’s Disease Treatment Business (2019-2024)
11.16.5 GSK Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
